Join our newsletter — 10% off your first order Join now
Blu Brain
What is methylene blue?

In enzyme assays, methylene blue directly inhibited nitric oxide synthase

Mark Kemp · 16 November 2026

In laboratory assays, methylene blue inhibited nitric oxide synthase directly and guanylyl cyclase far less potently than assumed. A plain summary of Mayer et al. 1993.

In assays on purified nitric oxide synthase from pig and cow tissue, methylthioninium chloride (methylene blue) blocked the enzyme's formation of L-citrulline — the co-product of nitric oxide — with half-maximal inhibition at 5.3 µM (9.2 µM with superoxide dismutase present) and complete inhibition at 30 µM (Mayer, Brunner & Schmidt, Biochem Pharmacol 1993). Soluble guanylyl cyclase, the enzyme methylene blue was long assumed to target, was far less sensitive: about 60 µM for half-inhibition, and no more than 72% even at 1 mM. The authors concluded that methylene blue is a direct inhibitor of nitric oxide synthase, and a much less specific and potent guanylyl cyclase inhibitor than previously thought.

Citation: Mayer B, Brunner F, Schmidt K. Biochem Pharmacol 1993;45(2):367–374. doi:10.1016/0006-2952(93)90072-5. PMID 7679577.

Why the question mattered

This is general biochemistry, not a description of what methylene blue does in the body. Nitric oxide is a signalling molecule. Cells lining blood vessels make it with nitric oxide synthase. It passes into the muscle layer and switches on soluble guanylyl cyclase, which makes cyclic GMP, and cyclic GMP relaxes the muscle. The discovery that nitric oxide works as a signalling molecule in the cardiovascular system earned Robert Furchgott, Louis Ignarro and Ferid Murad the 1998 Nobel Prize in Physiology or Medicine.

Methylene blue was one of the laboratory tools used in that research. In 1981, Gruetter, Kadowitz and Ignarro showed in strips of bovine coronary artery that it blocked relaxation caused by nitroglycerin (an organic nitrate) and by two nitrites, sodium nitrite and amyl nitrite — and that it blocked those compounds' activation of guanylyl cyclase. By the early 1990s methylene blue was widely used in laboratories as a guanylyl cyclase blocker: if it stopped an effect, the effect was taken to run through cyclic GMP. Mayer and colleagues tested whether that assumption held.

What the study did

Working with enzymes, blood vessels and cells from pigs and cattle, they measured methylene blue's effect on each step separately: purified nitric oxide synthase, tracked by the L-citrulline it makes; guanylyl cyclase switched on directly by a nitric oxide donor; and, in isolated blood vessels and cultured endothelial cells, responses that depend on the cells making their own nitric oxide. They ran the assays with and without superoxide dismutase, and checked whether methylene blue was simply oxidising the enzyme's cofactors.

What it found

Nitric oxide synthase was the sensitive target, at low micromolar concentrations. Guanylyl cyclase needed roughly ten times more methylene blue for the same effect, and was never fully blocked. In vessels and cells, responses that needed the cells' own nitric oxide were blocked more strongly than guanylyl cyclase switched on directly. Oxidation of NADPH, tetrahydrobiopterin or reduced flavins did not explain the result.

The tool used for more than a decade as a guanylyl cyclase blocker acts first on the enzyme that makes nitric oxide.

ModelPurified nitric oxide synthase; guanylyl cyclase; isolated blood vessels; cultured endothelial cells — pig and cow, not human
CompoundMethylthioninium chloride
MeasuredL-citrulline formation; guanylyl cyclase activity; endothelium-dependent relaxation; cyclic GMP
ResultNOS: IC50 5.3 µM (9.2 µM with SOD), full inhibition at 30 µM. Guanylyl cyclase: ~60 µM for 50%, 72% maximum at 1 mM
Not testedLive animals; humans; oral administration; any product

What it means, and what it doesn't

The paper is mainly a correction about a laboratory tool. Experiments that used methylene blue to prove cyclic GMP was involved may have been blocking nitric oxide production instead. For the molecule's chemistry, it shows that in these assays methylene blue acted on two enzymes in the nitric oxide pathway, and that the enzyme making nitric oxide was the more sensitive one.

Neither the 1993 nor the 1981 study shows anything about people. Both used purified enzymes and isolated tissue at micromolar concentrations in a laboratory, and those concentrations cannot be turned into an amount taken by mouth.

The question isn't fully settled. In a 2016 exchange of letters about methylene blue's intravenous use in hospital patients, Evora argued that it inhibits guanylate cyclase but does not interfere with nitric oxide synthesis. The authors he was answering cited this 1993 paper for the opposite view. Both sides agree on guanylyl cyclase; they differ on the synthase.

Read the paper

Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochemical Pharmacology 1993;45(2):367–374.

PubMed

DOI

Further reading

The 1981 guanylyl cyclase study — Gruetter, Kadowitz & Ignarro, Can J Physiol Pharmacol

The 2016 letter arguing the opposite — Evora, Texas Heart Institute Journal (free full text, with the authors' reply)

The 1998 Nobel Prize for nitric oxide signalling

Methylthioninium chloride on PubChem

This summarises a laboratory study on purified enzymes and isolated tissue. It is not evidence of an effect in humans and is not a claim about any product. If you take any prescription medicine, speak to a healthcare professional before using methylene blue.